NVP Healthcare
Quick facts
Phase 3 pipeline
- NVP-1203-R · Oncology
NVP-1203-R is a small molecule that targets the PD-1 receptor. - NVP-2203 · Oncology
NVP-2203 is a small molecule that targets the PD-1 receptor. - NVP-2203-R1 · Diabetes
NVP-2203-R1 is a small molecule that targets the SGLT2 receptor. - NVP-2203-R2 · Diabetes
NVP-2203-R2 is a small molecule that targets the SGLT2 receptor. - NVP-2203-R3 · Oncology
NVP-2203-R3 is a small molecule that targets the PD-1 receptor.
Phase 1 pipeline
- Ezetrol · Metabolic
- NVP-1203-R1
- NVP-1203-R1 and NVP-1203-R2
- NVP-1203-R2
- NVP-1205
- NVP-1402
- NVP-1402R
- NVP-1705
- NVP-1705-R
- NVP-1805
- NVP-1805-R1
- NVP-1805-R1 and NVP-1805-R2
- NVP-1805-R1and NVP-1805-R2
- NVP-1805-R2
- NVP-2002
- NVP-2102
- NVP-2102-R
- NVP-2203-R
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: